Crosslinked Versus Non‐Crosslinked Resorbable Collagen Membranes for Periodontal Regeneration: A Multicenter, Randomized, Double‐Blind, Non‐Inferiority Clinical Trial

• DOI: 10.1111/jre.13382
• Publication Date: 2025-01-12T13:33:36Z
• Authors: Yiwei Wang; Fuhua Yan; Lili Chen; Lei Zhao; Mo Liu; Shaohua Ge; Chia‐Yu Chen; David M. Kim; Rong Shu
• Keywords: Gingival recession; Clinical attachment loss; Bleeding on probing; Bone grafting

ABSTRACT Aim This study aimed to evaluate and compare the results of combination therapy involving bone grafting two different resorbable collagen membranes in 1‐, 2‐ 3‐wall infrabony defects. Methods A total 174 patients with defects (≥ 7 mm periodontal probing depth) were randomized receive deproteinized bovine mineral (DBBM) either a native porcine non‐crosslinked membrane (N‐CM, control, n = 87) or novel crosslinked (C‐CM, test, 87). Clinical parameters, including depth (PPD), clinical attachment level (CAL), gingival recession (GR), recorded at baseline, 12 weeks, 24 weeks. Radiographic evaluations measured linear gain (LBG) percentage fill (%BF) baseline Generalized Estimating Equations (GEE) used identify predictors outcomes. The primary outcome was effectiveness rate based on composite score integrating radiographic parameters Results One hundred seventy three completed study. At mean improvements PPD 4.17 ± 1.48 4.16 0.97 for control test groups, respectively, while CAL gains 3.69 1.32 3.60 1.81 mm. 3.12 2.19 group 3.00 1.92 group. Subgroup analysis showed trends favoring ( p 0.046) 0.042) 1‐wall 96.55% 95.35% group, difference −1.2% (95% CI: −5.88% 3.47%). Among those effective results, had higher proportion achieving significantly outcomes compared (96.5% vs. 86.2%, 0.032). Regression identified treatment defect morphology, as significant Conclusion demonstrated non‐inferiority regeneration. highlighted morphology key outcomes, subgroup suggested potential advantages C‐CM challenging morphologies, such These findings provide valuable insights into decision‐making. However, are limited by short‐term nature (24 weeks), further long‐term investigations needed confirm these preliminary assess their relevance. Trial Registration ClinicalTrials.gov identifier: NCT04851847